New drug combo aims to restore kidneys in myeloma patients
NCT ID NCT07085728
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study tests whether adding daratumumab to standard treatment (bortezomib and dexamethasone) can improve kidney function better than the usual approach (cyclophosphamide, bortezomib, and dexamethasone) in people newly diagnosed with multiple myeloma who also have kidney failure. About 74 adults will receive one of the two treatments for 4 months, then be followed for up to 10 years. The goal is to see which combination leads to better kidney recovery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIGHT CHAIN CAST NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alaska Oncology and Hematology LLC
Anchorage, Alaska, 99508, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo outsmart resistant myeloma?
- Real-world data on multiple myeloma immunotherapies could reshape monitoring and improve survival
- Could an ALS drug clear the fog of chemo brain?
- Immune cell 'Fitness' may predict success of advanced myeloma therapies in older patients
- Gene clues may unlock new treatments for bone marrow cancer
- New study monitors infection risks in blood cancer patients on bispecific antibodies